News
44m
MyChesCo on MSNMadrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is set to showcase critical new findings on resmetirom, its ...
53m
The Brighterside of News on MSNBreakthrough treatment offers new hope in the fight against fatty liver diseaseMetabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based ...
Recognizing the urgent need for intervention, a panel of experts has released new guidelines specifically for screening and ...
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...
Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), ...
Drinkers face another hike in the cost of alcohol under plans for a ramping-up of the SNP's controversial minimum pricing ...
Liver damage from alcohol can be reversed in some cases, but it depends on the severity of the damage. Here's what you need ...
Women with cirrhosis might notice their belly becoming swollen or bloated. This swelling is called ascites and happens ...
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
A recent clinical trial reveals that Wegovy, a popular weight-loss drug containing semaglutide, shows promising results in ...
Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results